TScan Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TCRX research report →
About the company
TScan Therapeutics, Inc. , a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism.
- CEO
- Gavin MacBeath
- IPO
- 2021
- Employees
- 143
- HQ
- Waltham, MA, US
Price Chart
- Market Cap
- $64.74M
- P/E
- -1.10
- P/S
- 7.09
- P/B
- 1.42
- EV/EBITDA
- -0.25
- Div Yield
- 0.00%
- Gross Margin
- 92.41%
- Op Margin
- -1408.73%
- Net Margin
- -1360.61%
- ROE
- -91.94%
- ROIC
- -67.93%
- Revenue
- $10.32M · 266.65%
- Net Income
- $-129,766,000 · -1.78%
- EPS
- $-1.00 · 12.28%
- Op Income
- $-135,813,000
- FCF YoY
- -21.87%
- 52W High
- $2.57
- 52W Low
- $0.82
- 50D MA
- $1.06
- 200D MA
- $1.23
- Beta
- 1.04
- Avg Volume
- 889.56K
Get TickerSpark's AI analysis on TCRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 20, 26 | BAKER BROS. ADVISORS LP | other | 67,000 |
| May 20, 26 | Woods Keith | other | 67,000 |
| May 20, 26 | Nicholson Garry A | other | 67,000 |
| May 20, 26 | Gruia Gabriela | other | 67,000 |
| May 20, 26 | Dorton Katina | other | 67,000 |
| May 20, 26 | Klencke Barbara | other | 67,000 |
| Jan 20, 26 | Amello Jason | other | 350,000 |
| Jan 20, 26 | MacBeath Gavin | other | 1,165,000 |
| Jan 20, 26 | Dworak Leiden | other | 100,000 |
| Jan 20, 26 | Louis Chrystal | other | 420,000 |
Our TCRX coverage
Recent articles, reports, and earnings notes.
No research on TCRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TCRX report →Similar companies
Peers in the same neighborhood.